EB
Emergent Bio
EBS·NYSEGaithersburg MDFounded 19982,300 employees
Small CapbiotechPublicInfectious Disease
Platform: Biodefense
Market Cap
$0.5B
All Drugs
2
Clinical Trials
4
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (EBS)
Loading EBS stock data...
Drug Pipeline (2 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Polamavacamten | EBS-924 | Phase 2 | 2 | LAG-3 | Endometrial CaMeso | ||
| Olpatinib | EBS-7359 | NDA/BLA | 2 | TNFα | Crohn'sDravet |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (4)